Sponsors & Marketing Authorization Holders
The product-owning companies — accountable for the whole lifecycle and for the oversight of every contract manufacturer, lab, CRO, and distributor they rely on.
Sponsors and Marketing Authorization Holders own the product and the marketing authorization. They may outsource manufacturing, testing, research, and distribution, but they remain accountable for the whole lifecycle — for the quality system that ties it together and for the oversight of every contract organization they rely on. The sponsor is the single point of accountability the health authority holds answerable.
The MAH’s duties span the pharmaceutical quality system (ICH Q10), outsourced-activity oversight (EU GMP Chapter 7), pharmacovigilance (EU GVP, with a Pharmacovigilance System Master File and a Qualified Person for Pharmacovigilance), batch certification by a Qualified Person in the EU, and the marketing-application obligations under FDA 21 CFR 314. It is the role that must see across every other sector in this list.
Accountability cannot be outsourced. The sponsor delegates work but retains responsibility: it qualifies and audits its CDMOs, labs, CROs, and distributors; it owns the overarching quality system and the product’s benefit-risk; and it answers to regulators for what its partners do. Effective, risk-based oversight — not just signed Quality Agreements — is what a modern inspection tests.
Supplier & partner oversight
Qualifying, auditing, and continuously overseeing every contract manufacturer, lab, CRO, and distributor — the core competency of an outsourced operating model.
The overarching quality system
An ICH Q10 pharmaceutical quality system that governs change, deviation, and CAPA across a network of external partners, not a single site.
Pharmacovigilance & benefit-risk
A functioning safety system (PSMF, QPPV) that maintains the product’s benefit-risk profile across its marketed life.
Lifecycle & maturity
Owning product knowledge, continued process verification, and the quality-management maturity that regulators increasingly assess at the enterprise level.
- ›Oversight that exists on paper (Quality Agreements) but is not exercised
- ›A quality system that cannot govern change and CAPA across external partners
- ›Pharmacovigilance obligations under-resourced relative to the marketed portfolio
- ›Loss of product/process knowledge when work is fully outsourced
Derived from the 83 standards SPEQ decodes for this sector.
Intelligence for Sponsors & Marketing Authorization Holders
The enforcement actions, guidance, and quality signals that shape sponsor–provider oversight — curated for Sponsors & Marketing Authorization Holders and delivered free each week.